	US 12,121,579 B2
	Antibodies specific to human t-cell immunoglobulin and ITIM domain (TIGIT)
Ofer Mandelboim, Shoham (IL); Noa S. Kaynan, Kibbutz Barkai (IL); Pinchas Tsukerman, Jerusalem (IL); and Stipan Jonjic, Rijeka (HR)
Assigned to YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., Jerusalem (IL); and UNIVERSITY OF RIJEKA FACULTY OF MEDICINE, Rijeka (HR)
Filed by YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., Jerusalem (IL); and UNIVERSITY OF RIJEKA FACULTY OF MEDICINE, Rijeka (HR)
Filed on Feb. 5, 2021, as Appl. No. 17/168,451.
Application 17/168,451 is a division of application No. 15/756,606, granted, now 10,946,095, previously published as PCT/IL2016/050952, filed on Sep. 1, 2016.
Claims priority of provisional application 62/314,427, filed on Mar. 29, 2016.
Claims priority of provisional application 62/213,140, filed on Sep. 2, 2015.
Prior Publication US 2021/0220472 A1, Jul. 22, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C12N 5/10 (2006.01); C12N 15/00 (2006.01); C12N 15/63 (2006.01); G01N 33/577 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/39558 (2013.01) [A61P 35/00 (2018.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); G01N 33/577 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12N 5/10 (2013.01); C12N 15/00 (2013.01); C12N 15/63 (2013.01)]

16 Claims

1. A polynucleotide comprising a sequence encoding the heavy and light chain variable regions of a monoclonal antibody or a fragment thereof, or a first polynucleotide and a second polynucleotide that comprise sequences encoding the heavy chain variable region and the light chain variable region, respectively, of the monoclonal antibody or fragment thereof, wherein the monoclonal antibody or fragment thereof is capable of binding to human T-cell immunoglobulin and ITIM domain (TIGIT), wherein the antibody fragment comprises at least the antigen binding portion of the monoclonal antibody, and wherein the antibody or fragment thereof is selected from the group consisting of:

(i) an antibody or fragment thereof comprising six complementarity determining regions (CDRs), wherein the heavy chain (HC) CDR1 comprises the sequence GYTFTSYGIS (SEQ ID NO:1) or TSYGIS (SEQ ID NO:11); the HC CDR2 comprises the sequence: EIYPRSGNTYYNEKFKG (SEQ ID NO:2); the HC CDR3 comprises the sequence: KGPYYTKNEDY (SEQ ID NO:3); the light chain (LC) CDR1 comprises the sequence: RASEHIYYSLA (SEQ ID NO:4); the LC CDR2 comprises the sequence: NANSLED (SEQ ID NO:5); and the LC CDR3 comprises the sequence: KQAYDVPRT (SEQ ID NO: 6); and

(ii) an antibody or fragment thereof comprising six CDRs, wherein the HC CDR1 comprises the sequence IYCIH (SEQ ID NO:12); the HC CDR2 comprises the sequence: EISPSNGRTIYNEKFKN (SEQ ID NO:13); the HC CDR3 comprises the sequence: SDGYDGYYFDY (SEQ ID NO:14); LC CDR1 comprises the sequence: RASQEISGYLN (SEQ ID NO:15); the LC CDR2 comprises the sequence: AASTLDS (SEQ ID NO:16); and the LC CDR3 comprises the sequence: LQYASYPRT (SEQ ID NO:17).